Through in vitro and in vivo assays, including promoter deactivation and GFP reporter assays, 6‐TG demonstrated a capacity to diminish BACE1 expression and Aβ production, suggesting a restorative effect on synaptic density and cognitive functions in AD models. The gene discussed is BACE1; the disease is Alzheimer disease.